Personal Profile
Cai Jing is currently an Associate Professor and Master's Supervisor at Zhongshan School of Medicine, Sun Yat-sen University. She earned her Bachelor of Science degree from the School of Life Sciences at Sun Yat-sen University in 2013 and her Ph.D. in Science from Zhongshan School of Medicine, Sun Yat-sen University in 2017. From 2018 to 2022, she worked as a full-time researcher (Postdoctoral Fellow and Special-Term Associate Researcher) at Zhongshan School of Medicine.

Research Focus
Her research focuses on oncolytic virotherapy. The development of novel and effective anticancer drugs and therapies remains a critical demand for both society and scientific advancement. Oncolytic virotherapy is an emerging and highly regarded field within the broader scope of cancer immunotherapy. Her major discoveries include:

1. Identifying a novel mechanism of oncolytic virus M1's tumor-killing advantage: the bystander killing effect;
2. Determining the specific membrane receptor of oncolytic virus M1, laying the scientific foundation for its precision therapy;
3. Defining the zinc-finger antiviral protein ZAP in tumor host cells as a new tumor suppressor gene;
4. Elucidating the mechanisms of tumor resistance to oncolytic virus M1, contributing to the long-term cure of certain cancers.

She has published over 10 SCI-indexed papers as the first or corresponding author and has led six research projects, including two National Natural Science Foundation of China (NSFC) grants and one China Postdoctoral Innovative Talent Support Program.

Academic Achievements
Representative academic publications:
1.    Song D#, Jia X#, Liu X#, Hu L#, Lin K, Xiao T, Qiao Y, Zhang J, Dan J, Wong C, Hu C, Sai K, Gong S, Sander M, Shen R, Chen X, Xiao X, Chen J, Zhang Y, Wei C, Xiao X, Liang J, Zhang Q, Hu J, Zhu W, Yan G, Lin Y*, Cai J*. Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors. Signal Transduction and Targeted Therapy. 2022;7(1):100.

2.    Liu Y#, Xu C, Xiao X, Chen Y, Wang X, Liu W, Tan Y, Zhu W, Hu J, Liang J, Yan G, Lin Y*, Cai J*. Overcoming resistance to oncolytic virus M1 by targeting PI3K-gamma in tumor-associated myeloid cells. Molecular Therapy. 2022.

3.    Cai J#, Liu W, Wong CW, Zhu W, Lin Y, Hu J, Xu W, Zhang J, Sander M, Wang Z, Dan J, Zhang J, Liu Y, Guo L, Qin Z, Liu X, Liu Y, Yan G, Wu S*, Liang J*. Zinc-finger antiviral protein acts as a tumor suppressor in colorectal cancer. Oncogene. 2020;39(37):5995-6008.

4.    Sun S#, Liu Y#, He C, Hu W, Liu W, Huang X, Wu J, Xie F, Chen C, Wang J, Lin Y, Zhu W, Yan G, Cai J*, Li S*. Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer. Cancer Letters. 2021;502:9-24.

5.    Liu Y#, Cai J#, Liu W, Lin Y, Guo L, Liu X, Qin Z, Xu C, Zhang Y, Su X, Deng K, Yan G, Liang J*. Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade. Cell Death & Disease. 2020;11(12):1062.

6.    Cai J#, Lin Y#, Zhang H, Liang J, Tan Y, Cavenee WK*, Yan G*. Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics. PNAS. 2017;114(26):6812-7.

7.    Xing F#, Luan Y#, Cai J#, Wu S, Mai J, Gu J, Zhang H, Li K, Lin Y, Xiao X, Liang J, Li Y, Chen W, Tan Y, Sheng L, Lu B, Lu W, Gao M, Qiu P, Su X, Yin W, Hu J, Chen Z, Sai K, Wang J, Chen F, Chen Y, Zhu S, Liu D, Cheng S, Xie Z*, Zhu W*, Yan G*. The Anti-Warburg Effect Elicited by the cAMP-PGC1alpha Pathway Drives Differentiation of Glioblastoma Cells into Astrocytes. Cell Reports. 2017;18(2):468-81.